Camptothecin Block Copolymer pH Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical preparations of polymerized camptothecin derivatives lack stability in maintaining nanoparticle-forming properties, leading to reduced efficacy and increased side effects due to molecular weight changes during storage.
Innovation Solution
A pharmaceutical preparation comprising a block copolymer with a polyethylene glycol segment linked to a polyglutamic acid segment, where the camptothecin derivative is bonded, maintaining associative properties by adjusting the pH of the aqueous solution to 2.4-7.0, thereby stabilizing nanoparticle formation and molecular weight during storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the polymerized camptothecin derivative is stored as a pharmaceutical preparation, then the drug can be administered for antitumor treatment, but the nanoparticle-forming properties deteriorate over time due to molecular weight changes
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the aqueous solution to a specific range (pH 2.0-7.0, preferably pH 3.0-6.0) to stabilize the nanoparticle-forming properties of the polymerized camptothecin derivative during storage. This pH control prevents molecular weight changes and maintains the associate-forming ability, directly resolving the contradiction between storage duration and reliability of nanoparticle properties
Solution Approach 2:
The patent implements preliminary action by adjusting the pH to the optimal range before storage begins. This preliminary pH adjustment ensures that the polymerized camptothecin derivative maintains stable nanoparticle-forming properties throughout the storage period, preventing deterioration before it can occur
2Ease of manufacture
If the molecular weight of the polymer carrier changes during storage, then the preparation is easier to manufacture without strict pH control, but the antitumor efficacy is reduced and side effects increase
Solution Approach 1:
The patent applies parameter changes by establishing a specific pH range (pH 2.0-7.0) that simultaneously achieves two goals: it maintains the molecular weight stability required for antitumor efficacy while remaining compatible with standard pharmaceutical manufacturing processes. This resolves the contradiction by showing that strict pH control within this range does not significantly complicate manufacturing but effectively prevents side effects
Solution Approach 2:
The patent employs pH adjusting agents and buffers that are inexpensive and commonly used in pharmaceutical manufacturing, making the pH control strategy economically viable and easy to implement without requiring complex or expensive manufacturing modifications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The preparation ensures long-term storage stability of nanoparticle-forming properties, enhancing the antitumor effect while reducing side effects by maintaining the desired molecular weight and particle size of the camptothecin derivative.
Implementation Method 1
these block copolymers having antitumor agents bonded thereto have a physical property by which, when the block region to which the antitumor agent is bonded is hydrophobic, the antitumor agent-bonded region in an aqueous solution exhibits associative properties based on a hydrophobic interaction, and a plurality of the molecules of the block copolymer form associates through aggregation
Data Source
AI summary
Provided is a pharmaceutical preparation composition comprising a polymerized camptothecin derivative which is obtained by bonding a camptothecin derivative to a polymer carrier, and has nanoparticle-forming properties of associating in an aqueous solution, the pharmaceutical preparation composition having enhanced preparation stability. Particularly, a pharmaceutical preparation maintaining nanoparticle-forming properties, which are an important factor, and having an excellent storage stability is provided.Disclosed is a pharmaceutical preparation comprising a block copolymer in which a polyethylene glycol segment is linked to a polyglutamic acid segment containing a glutamic acid unit having a camptothecin derivative bonded thereto, the pharmaceutical preparation capable of forming associates in an aqueous solution. When the pharmaceutical preparation is made into an aqueous solution containing the camptothecin derivative at a concentration of 1 mg/mL, the pH of the aqueous solution is 2.4 to 7.0, and the change ratio of the associate-forming ability of the pharmaceutical preparation after storage at 40° C. for one week under light-blocked conditions is 50% or less.